Legend Biotech Corp ADR (NASDAQ:LEGN) has a beta value of 0.10 and has seen 2.78 million shares traded in the last trading session. The company, currently valued at $8.23B, closed the last trade at $44.91 per share which meant it lost -$4.77 on the day or -9.60% during that session. The LEGN stock price is -57.6% off its 52-week high price of $70.78 and 14.05% above the 52-week low of $38.60. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.95 million shares traded. The 3-month trading volume is 895.42K shares.
The consensus among analysts is that Legend Biotech Corp ADR (LEGN) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 11 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.43.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Sporting -9.60% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the LEGN stock price touched $44.91 or saw a rise of 13.25%. Year-to-date, Legend Biotech Corp ADR shares have moved -25.36%, while the 5-day performance has seen it change -6.55%. Over the past 30 days, the shares of Legend Biotech Corp ADR (NASDAQ:LEGN) have changed -12.44%. Short interest in the company has seen 12.07 million shares shorted with days to cover at 12.36.
Wall Street analysts have a consensus price target for the stock at $86, which means that the shares’ value could jump 47.78% from current levels. The projected low price target is $60.0 while the price target rests at a high of $94.0. In that case, then, we find that the current price level is -109.31% off the targeted high while a plunge would see the stock gain -33.6% from current levels.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Figures show that Legend Biotech Corp ADR shares have underperformed across the wider relevant industry. The company’s shares have lost -10.40% over the past 6 months, with this year growth rate of -2.72%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be 105.10%.
13 analysts offering their estimates for the company have set an average revenue estimate of 138.09M for the current quarter. 13 have an estimated revenue figure of 177.5M for the next ending quarter. Year-ago sales stood 96.01M and 79.46M respectively for this quarter and the next, and analysts expect sales will grow by 43.80% for the current quarter and 105.10% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -168.48% over the past 5 years.
LEGN Dividends
Legend Biotech Corp ADR is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
The top two institutional holders are FMR LLC with over 17.62 million shares worth more than $780.46 million. As of 2024-06-30, FMR LLC held 9.6819% of shares outstanding.
The other major institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, with the holding of over 11.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $508.86 million and represent 6.3126% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Health Care and Price (T.Rowe) Growth Stock Fund Inc. . As of Aug 31, 2024 , the former fund manager holds about 1.37% shares in the company for having 2.5 shares of worth $112.27 million while later fund manager owns 2.4 shares of worth $107.75 million as of Jun 30, 2024 , which makes it owner of about 1.32% of company’s outstanding stock.
